REVENUE INTEREST FINANCING AGREEMENT by and between NUVATION BIO INC., as the Company, and SAGARD HEALTHCARE PARTNERS (DELAWARE) II LP, as the Investor Dated March 3, 2025Revenue Interest Financing Agreement • March 6th, 2025 • Nuvation Bio Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 6th, 2025 Company Industry JurisdictionThis REVENUE INTEREST FINANCING AGREEMENT (this “Agreement”) dated as of March 3, 2025 is by and between Nuvation Bio Inc., a Delaware corporation (the “Company”), and Sagard Healthcare Partners (Delaware) II LP, a Delaware limited partnership (the “Investor”). Each of the Company and the Investor are referred to in this Agreement as a “Party” and collectively as the “Parties”.
REVENUE INTEREST FINANCING AGREEMENT by and between MARINUS PHARMACEUTICALS, INC., as the Company, and SAGARD HEALTHCARE ROYALTY PARTNERS, LP, as the Investor Dated October 28, 2022Revenue Interest Financing Agreement • November 7th, 2022 • Marinus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 7th, 2022 Company Industry JurisdictionThis REVENUE INTEREST FINANCING AGREEMENT (this “Agreement”) dated as of October 28, 2022 is by and between MARINUS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempted limited partnership (the “Investor”). Each of the Company and the Investor are referred to in this Agreement as a “Party” and collectively as the “Parties”.